A Network Meta-Analysis of Headache Risk in Type 2 Diabetes Patients Caused by SGLT-2 Inhibitors

Abstract

Abstract: Objective：To evaluate the risk of headache in patients with type 2 diabetes(T2DM) treated with different SGLT-2 inhibitors. Methods：The literatures on different SGLT-2 inhibitors for the treatment of type 2 diabetes published in the databases（from the establishment to October 15， 2022）was retrieved， and then the literatures screening and data extraction were performed， the network Meta analysis was performed with Stata 15.1 software. Results： A total of 20 articles were included， and the results of network meta-analysis showed that， compared with Dapagliflozin 20 mg and Dapagliflozin 10 mg， Canagliflozin 100 mg and Canagliflozin 300 mg increased the incidence of headache adverse reactions in patients with type 2 diabetes during drug administration. The risk of headache in patients with type 2 diabetes was increased by using Ertugliflozin10 mg compared withCanagliflozin 300 mg and Canagliflozin 100 mg.At the same time，compared with Ipragliflozi 200 mg and Ipragliflozi 300 mg，Canagliflozin 100 mg， can increase the occurrence of headache adverse reactions in patients with type 2 diabetes. Conclusion：In order to reduce the occurrence of headache adverse reactions as much as possible when using different doses of SGLT-2 inhibitors in the treatment of type 2 diabetes， Dapagliflozin20 mg， Ipragliflozi 300 mg and Ipragliflozi 200 mg should be given priority. Type 2 diabetes patients are more prone to headache adverse reactions when using Canagliflozin 300 mg and Canagliflozin 100 mg.

Key words: font-size:medium, ">Sodium glucose cotransporter-2 inhibitor； Headache； Type 2 diabetes； Mesh Meta analysis

CLC Number:

ZHUO Jun, XIE Zhuolin, LING Juan, LEI Kangqing, JIANG Yan, GUO Kangle, TIAN Yan. A Network Meta-Analysis of Headache Risk in Type 2 Diabetes Patients Caused by SGLT-2 Inhibitors[J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(2): 167-172.

References

[1]Lee PC，Ganguly S， Goh SY. Weight loss associated with sodium-glucose cotransporter-2 inhibition： a review of evidence and underlying mechanisms： SGLT2 inhibitor-mediated weight loss[J]. Obesity Reviews，2018，19(Suppl 1).
     [2]李鑫，李焕德.一类全新机制的2型糖尿病治疗药物SGLT2抑制剂[J]. 中南药学，2018， 16(3)：8.
     [3]Nagano Y， Yakame NK， Aoki H， et al. Fournier′s Gangrene in a Patient with Type 2 Diabetes Mellitus Treated with Empagliflozin： A Case Report[J]. Drug Safety， 2019， 6(1)：1-5.
     [4]Scheen， André J. An update on the safety of SGLT2 inhibitors[J]. Expert Opin Inv Drug，2019.
     [5]Wilding JP， Norwood P， T′Joen C， et al.A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers： applicability of a novel insulin-independent treatment[J]. Diabetes Care， 2009， 32(9)：1656-1662.
     [6]Bailey CJ， Gross JL， Pieters A， et al.Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin： a randomised， double-blind，placebo-controlled trial[J]. Lancet(london，england) 2010，375(9733)：2223-2233.
     [7]Devineni D， Morrow L， Hompesch M， et al.Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin[J]. Diabetes Obes Metab，2012， 14(6)：539-545.
     [8]Rosenstock J， Jelaska A， Frappin G，et al. Improved glucose control with weight loss， lower insulin doses， and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes[J]. Diabetes Care，2014，37(7)：1815-1823.
     [9]Wilding JP， Woo V， Rohwedder K，et al. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin： efficacy and safety over 2 years[J]. Diabetes Obes Metab，2014， 16(2)：124-136.
     [10]Amin NB， Wang X， Jain SM，et al.Dose-ranging efficacy and safety study of ertugliflozin， a sodium-glucose co-transporter 2 inhibitor， in patients with type 2 diabetes on a background of metformin[J]. Diabetes Obes Metab，2015，17(6)：591-598.
     [11]Bailey CJ， Morales Villegas EC， Woo V， et al. Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes： a randomized double-blind placebo-controlled 102-week trial[J]. Diabetic Med，2015，32(4)：531-541.
     [12]Ferrannini E， Ramos SJ， Salsali A，et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise： a randomized， double-blind， placebo-controlled， phase 3 trial[J]. Diabetes Care，2010， 33(10)：2217-2224.
     [13]Schwartz SL， Akinlade B， Klasen S， et al. Safety， pharmacokinetic， and pharmacodynamic profiles of ipragliflozin(ASP1941)， a novel and selective inhibitor of sodium-dependent glucose co-transporter 2， in patients with type 2 diabetes mellitus[J]. DIABETES TECHNOL THE. 2011，13(12)：1219-1227.
     [14]Rosenstock J， Zambrowicz B， Lapuerta P， et al.Impact of LX4211， a dual inhibitor of sodium glucose transporter 1 and 2 on cardiovascular risk factors in type 2 diabetes[J]. Circulation，2012，126(23)：2790.
     [15]Bode B， Stenlf K， Sullivan D， et al.Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus： a randomized trial[J]. Hosp Pract，2013，41(2)：72-84.
     [16]Ferrannini E， Seman L， Seewaldt-Becker E， et al.A Phase IIb， randomized， placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes[J]. Diabetes Obes Metab，2013，15(8)：721-728.
     [17]Yale JF， Bakris G， Cariou B， et al.Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease[J]. Diabetes Obes Metab，2013，15(5)：463-473.
     [18]Wilding JP， Woo V， Soler NG， et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin[J]. Deut Med Wochenschr， 2013， 138(1)：S27-38.
     [19]Kaku K， Inoue S， Matsuoka O，et al.Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control： a phase II multicentre， randomized， double-blind， placebo-controlled trial[J]. Diabetes Obes Metab，2013， 15(5)：432-440.
     [20]Rosenstock J， Seman LJ， Jelaska A，et al.Efficacy and safety of empagliflozin， a sodium glucose cotransporter 2(SGLT2) inhibitor， as add-on to metformin in type 2 diabetes with mild hyperglycaemia[J]. Diabetes Obes Metab，2013， 15(12)：1154-1160.
     [21]Stenlf K， Cefalu WT， Kim KA， et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise[J]. Diabetes Obes Metab，2013， 15(4)：372-382.
     [22]Weir MR， Januszewicz A， Gilbert RE， et al. Effect of Canagliflozin on Blood Pressure and Adverse Events Related to Osmotic Diuresis and Reduced Intravascular Volume in Patients With Type 2 Diabetes Mellitus[J]. J Clin Hypertens，2014， 16(12)：875-882.
     [23]Yamout H， Perkovic V， Davies M， et al.Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy[J]. Am J Nephrol，2014， 40(1)：64-74.
     [24]Terra SG， Focht K， Davies M， et al.Phase III， efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone[J]. Diabetes Obes Metab，2017， 19(5)：721-728.
     [25]Garcia-Ropero A， Badimon JJ， Santos-Gallego CG. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus： the latest developments[J]. Expert Opin Drug Met，2018；14(12)：1287-1302.
     [26]Cuypers J， Mathieu C， Benhalima K. SGLT2-inhibitors： a novel class for the treatment of type 2 diabetes introduction of SGLT2-inhibitors in clinical practice[J]. Acta Clin Belg，2013，68(4)：287-293.
     [27]Cefalu WT， Buse JB， Tuomilehto J， et al. Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention： Reflections From a Diabetes Care Editors′ Expert Forum[J]. Diabetes Care，2016；39(7)：1186-1201.
     [28]Chawla G， Chaudhary KK. A complete review of empagliflozin： Most specific and potent SGLT2 inhibitor used for the treatment of type 2 diabetes mellitus[J]. Diabetes Metab Synd， 2019， 13(3)：2001-2008.
     [29]Scheen AJ. Pharmacodynamics， efficacy and safety of sodium-glucose co-transporter type 2(SGLT2) inhibitors for the treatment of type 2 diabetes mellitus[J]. Drugs，2015，75(1)：33-59.
     [30]林纬，陈刚. 2018 ADA/EASD 2型糖尿病高血糖管理共识声明解读——新策略、新理念、新挑战[J]. 中国医学前沿杂志， 2018， 10(10)：3.
     [31]Storgaard H，Bagger JI， Knop FK，et al.Diabetic Ketoacidosis in a Patient with Type 2 Diabetes After Initiation of Sodium–Glucose Cotransporter 2 Inhibitor Treatment[J]. Basic Clin Pharmacol， 2016， 118(2).

A Network Meta-Analysis of Headache Risk in Type 2 Diabetes Patients Caused by SGLT-2 Inhibitors

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	DAI Qi, LI Kang-xi, YE Qiao-bo, WEN Yong-sheng, XU Li, LI Ji. Reaserch Progress on Chemical Constituents，Pharmacological Effects and Toxicology of Bombyx Batryticatus [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 402-408.
[2]	ZHAO Lei, YANG Ming, WANG Hao, MA yu, MA Jin-gan, JIANG Da-cheng, WANG Lu-hong, ZAN Ke. Investigation and Risk Assessment of Mycotoxins in Seabuckthorn during Different Harvesting Periods and Drying Processes [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 377-383.
[3]	HONG Shu-hua, LIN Qi-shan, CHAI Jiang-hong, PAN Hong-ju. Study on the Determination of Zopiclone Related Substances and the Influence of Correction Factor [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 384-388.
[4]	LI Yue-chen, CUI Shao-jing, ZHAO Yue-ran. Determination of Aflatoxins in Huoxuezhitong Capsules by High Performance Liquid Chromatography Coupled with Post-column Photochemical Derivatization [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 390-395.
[5]	TIAN Jie, HAO Ai-yu, LU Lin, ZOU Pian, DONG Bin. Effect of Several Drug Compatibility on Sub-visible Particles in Infusions with Common Plastic Packagings [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 396-401.
[6]	YANG Yan-qing, CHEN Chun-mei, CHEN Wei, Wu Rui, WANG Xue-chang, DUAN Lian. Rapid Health Technology Evaluation of Sintilimab as First-line Treatment for Advanced Non-small Cell Lung Cancer [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 409-415.
[7]	JIANG Yi-Fan, CHEN Li-ping, ZHANG Ruo-yu, WU Pei-hao, QIU Jia-min, XUAN Jian-wei, BI Hui-chang. Construction of Clinical Comprehensive Value Evaluation System for Acid-inhibiting Drugs [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 416-421.
[8]	HUA Min-fan, SONG Cang-sang, LI Xing-de, LU Wei, MAO Pan-pan, WANG Guo-hui. Medication Adherence Forecast Model Research Progress in Clinical Application [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 422-425.
[9]	HUANG Bo, CAO Xiao-ming. Safety Analysis of Isotonic and Hypotonic Contrast Media for Coronary Angiography in Elderly Patients with Renal Impairment [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 426-429.
[10]	ZHANG Wen, YANG Wei-bing. Effects of Vitamin D Combined with Etocoxib on Rehabilitation，Bone Metabolism and Inflammation in Elderly Patients after Knee Replacement [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 430-434.
[11]	TIAN Jin-ya, DUAN Xiao-kai, FAN Shi-zhen. Effects of Budesonide combined with Ipratropium Bromide Solution on Lung Function， Blood Gas Analysis and Th1/Th2 Cytokines with Chronic Bronchitis [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 435-438.
[12]	ZHANG He-feng, LIANG Yu, LIU Ying, ZOU Ling-long, . Introduction of Bioanalytical Strategies and Methodologies for Genetically Modified Cell Therapy Products [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 369-376.
[13]	ZHANG He-feng, LIANG Yu, LIU Ying, ZOU Ling-long, . Bioanalysis of Gene Therapy Products： Method Development Strategy [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 361-368.
[14]	ZHANG Yu, LI Yu-man, XIA Xu-dong. Analysis of Suspected ADR Monitoring Data of Ginkgo Injection Preparations [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 439-444.
[15]	YAO Qing, LIU Ying, WANG Xiao-fang, GAO Ning, WANG Miao. Excel Calculates the Population Bioequivalence of Special Preparations [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(4): 332-337.